Gaucher's Market Research Reports & Industry Analysis
Gaucher's Industry Research & Market Reports
-
Gaucher Disease Market Report: Trends, Forecast and Competitive Analysis to 2030
... markets. The global gaucher disease market is expected to reach an estimated $2.0 billion by 2030 with a CAGR of 2.1% from 2024 to 2030. The major drivers for this market are the increasing prevalence ... Read More
-
Global Pompe Disease Therapeutics Market - 2023-2030
... The global Pompe disease therapeutics market is expected to exhibit a CAGR of 4.3% during the forecast period (2023-2030). Pompe disease is an inherited lysosomal condition induced by a lack of the enzyme acid alpha-glucosidase ... Read More
-
Global Gaucher’s Disease Treatment Market Growth 2023-2029
... at a CAGR of 3.7% from 2023 to 2029. United States market for Gaucher’s Disease Treatment is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % ... Read More
-
2023 Global: Gaucher And Pompe Diseases Enzyme Replacement Therapy (Ert) Market - Innovative Markets Forecast (2029) report
... analyzies the market size, projected growth/decline and regional data for the period 2018 through 2029. Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product ... Read More
-
2023 Global Forecast for Gaucher And Pompe Diseases Enzyme Replacement Therapy (Ert) Market (2024-2029 Outlook)-High Tech & Emerging Markets Report
... the market for over 50 countries. The product or service category is within the NAICS Medical Laboratories industry. The product or service category is within the NAICS Medical Laboratories industry. The global market is expected ... Read More
-
Plant-Based Biologics Market By Product Type (Leaf-based, Seed-Based, Fruit-based, Others), By Source (Carrot, Tobacco, Rice, Duckweed, Others), By Target Disease (Gaucher Disease, Fabry Disease, Others): Global Opportunity Analysis and Industry Forecast, 2021-2031
... biologics market is envisioned to garner $182.9 million by 2031, growing from $116.1 million in 2021 at a CAGR of 4.8% from 2022 to 2031. The current production platforms, which are mostly based on mammalian ... Read More
-
Gaucher Disease Pipeline Report, 2023- Planned Drugs by Phase, Mechanism of Action, Route of Administration, Type of Molecule, Market Trends, Developments, and Companies
... clinical stage pipeline candidates under development as of H1- 2023. For each of the Gaucher Disease pipeline candidate, details of leading companies, phase of development, mechanism of action, route of administration, molecule type, and other ... Read More
-
Gaucher’s Disease - Drug Pipeline Landscape, 2023
... including the spleen and liver. The condition is mainly of 3 types: Gaucher disease type 1, Gaucher disease type 2, and Gaucher disease type 3. Gaucher Disease's main cause is mutations in the GBA1 gene, ... Read More
-
Global Enzyme Replacement Therapy Market Size study & Forecast, by Product (Agalsidase Beta, Imiglucerase, Velaglucerase Alfa, Idursulfase, Galsulfase, Laronidase, Others) by Disease (Gaucher Disease, Fabry Disease, Pompe Disease, Mucopolysaccharidosis, Exocrine Pancreatic Insufficiency (EPI), Others), by End User (Hospitals, Infusion Centers & Home Healthcare Setting) and Regional Analysis, 2022-2029
... End User (Hospitals, Infusion Centers & Home Healthcare Setting) and Regional Analysis, 2022-2029 Global Enzyme Replacement Therapy Market is valued approximately USD XXX billion in 2021 and is anticipated to grow with a healthy growth ... Read More
-
Virus-Like Particles (VLP’s) Market Analysis And Forecast To 2032: By Product Type (Hepatitis, Cancer/HPV, Gaucher Disease), Source (Yeast, Insect Cell, Plant, Others), Application (Vaccine, Therapeutics), And Region
... period. Virus-like particles (VLPs) are multiprotein structures that mimic the organization and conformation of authentic native viruses but lack the viral genome, potentially yielding safer and cheaper vaccine candidates. Market Trends and Drivers Consistent R&D ... Read More
-
Gaucher Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... provides an overview of the Gaucher Disease (Genetic Disorders) pipeline landscape. Gaucher disease is a rare genetic disorder occurs due to lacks an enzyme called glucocerebrosidase. Symptoms include cognitive impairment, enlarged spleen, severe swelling, lung ... Read More
-
North America Glycomic Therapeutics Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – Class (Isolated and Synthetic), Structures [Glycoproteins, Targeting Sialic Acid, Proteoglycans, Targeting Glycosaminoglycans, Glycosylphosphatidylinositol (GPI)-Anchored Proteins & Heparin Based Glycans, Targeting Glycosphingolipids, and Others], Indications (Thrombosis & Chemoprophylaxis, Anaemia, Anti-Adhesive & Anti-Inflammatory, Cataracts, Gaucher’s Disease, MPS-1 & IV, Cancer, Alzheimer’s Disease, Influenza Type A & B, and Others), Mode of Action [Inhibits Neuraminidase, Inhibits Heparanase and Selectins and Blocks Interactions Between Growth Factors and Heparan Sulfate, Erythropoietin & Enzyme Replacement Therapy (ERT),Tissue Plasminogen Activator, Inhibits Glucosylceramide Synthas Interleukin 1 and 2 and 3, Beta & Gamma Interferons, and Others]
... Glycosphingolipids, and Others], Indications (Thrombosis & Chemoprophylaxis, Anaemia, Anti-Adhesive & Anti-Inflammatory, Cataracts, Gaucher’s Disease, MPS-1 & IV, Cancer, Alzheimer’s Disease, Influenza Type A & B, and Others), Mode of Action [Inhibits Neuraminidase, Inhibits Heparanase and ... Read More
-
Asia Pacific Glycomic Therapeutics Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – Class (Isolated and Synthetic), Structures [Glycoproteins, Targeting Sialic Acid, Proteoglycans, Targeting Glycosaminoglycans, Glycosylphosphatidylinositol (GPI)-Anchored Proteins & Heparin Based Glycans, Targeting Glycosphingolipids, and Others], Indications (Thrombosis & Chemoprophylaxis, Anaemia, Anti-Adhesive & Anti-Inflammatory, Cataracts, Gaucher’s Disease, MPS-1 & IV, Cancer, Alzheimer’s Disease, Influenza Type A & B, and Others), Mode of Action [Inhibits Neuraminidase, Inhibits Heparanase and Selectins and Blocks Interactions Between Growth Factors and Heparan Sulfate, Erythropoietin & Enzyme Replacement Therapy (ERT), Tissue Plasminogen Activator, Inhibits Glucosylceramide Synthas Interleukin 1 and 2 and 3, Beta & Gamma Interferons, and Others]
... Glycosphingolipids, and Others], Indications (Thrombosis & Chemoprophylaxis, Anaemia, Anti-Adhesive & Anti-Inflammatory, Cataracts, Gaucher’s Disease, MPS-1 & IV, Cancer, Alzheimer’s Disease, Influenza Type A & B, and Others), Mode of Action [Inhibits Neuraminidase, Inhibits Heparanase and ... Read More
-
Middle East & Africa Glycomic Therapeutics Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – Class (Isolated and Synthetic), Structures [Glycoproteins, Targeting Sialic Acid, Proteoglycans, Targeting Glycosaminoglycans, Glycosylphosphatidylinositol (GPI)-Anchored Proteins & Heparin Based Glycans, Targeting Glycosphingolipids, and Others], Indications (Thrombosis & Chemoprophylaxis, Anaemia, Anti-Adhesive & Anti-Inflammatory, Cataracts, Gaucher’s Disease, MPS-1 & IV, Cancer, Alzheimer’s Disease, Influenza Type A & B, and Others), Mode of Action [Inhibits Neuraminidase, Inhibits Heparanase and Selectins and Blocks Interactions Between Growth Factors and Heparan Sulfate, Erythropoietin & Enzyme Replacement Therapy (ERT), Tissue Plasminogen Activator, Inhibits Glucosylceramide Synthas Interleukin 1 and 2 and 3, Beta & Gamma Interferons, and Others]
... Glycans, Targeting Glycosphingolipids, and Others], Indications (Thrombosis & Chemoprophylaxis, Anaemia, Anti-Adhesive & Anti-Inflammatory, Cataracts, Gaucher’s Disease, MPS-1 & IV, Cancer, Alzheimer’s Disease, Influenza Type A & B, and Others), Mode of Action [Inhibits Neuraminidase, Inhibits ... Read More
-
South & Central America Glycomic Therapeutics Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – Class (Isolated and Synthetic), Structures [Glycoproteins, Targeting Sialic Acid, Proteoglycans, Targeting Glycosaminoglycans, Glycosylphosphatidylinositol (GPI)-Anchored Proteins & Heparin Based Glycans, Targeting Glycosphingolipids, and Others], Indications (Thrombosis & Chemoprophylaxis, Anaemia, Anti-Adhesive & Anti-Inflammatory, Cataracts, Gaucher’s Disease, MPS-1 & IV, Cancer, Alzheimer’s Disease, Influenza Type A & B, and Others), Mode of Action [Inhibits Neuraminidase, Inhibits Heparanase and Selectins and Blocks Interactions Between Growth Factors and Heparan Sulfate, Erythropoietin & Enzyme Replacement Therapy (ERT), Tissue Plasminogen Activator, Inhibits Glucosylceramide Synthas Interleukin 1 and 2 and 3, Beta & Gamma Interferons, and Others]
... Glycans, Targeting Glycosphingolipids, and Others], Indications (Thrombosis & Chemoprophylaxis, Anaemia, Anti-Adhesive & Anti-Inflammatory, Cataracts, Gaucher’s Disease, MPS-1 & IV, Cancer, Alzheimer’s Disease, Influenza Type A & B, and Others), Mode of Action [Inhibits Neuraminidase, Inhibits ... Read More
-
Europe Glycomic Therapeutics Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – Class (Isolated and Synthetic), Structures [Glycoproteins, Targeting Sialic Acid, Proteoglycans, Targeting Glycosaminoglycans, Glycosylphosphatidylinositol (GPI)-Anchored Proteins & Heparin Based Glycans, Targeting Glycosphingolipids, and Others], Indications (Thrombosis & Chemoprophylaxis, Anaemia, Anti-Adhesive & Anti-Inflammatory, Cataracts, Gaucher’s Disease, MPS-1 & IV, Cancer, Alzheimer’s Disease, Influenza Type A & B, and Others), Mode of Action [Inhibits Neuraminidase, Inhibits Heparanase and Selectins and Blocks Interactions Between Growth Factors and Heparan Sulfate, Erythropoietin & Enzyme Replacement Therapy (ERT), Tissue Plasminogen Activator, Inhibits Glucosylceramide Synthas Interleukin 1 and 2 and 3, Beta & Gamma Interferons, and Others]
... and Others], Indications (Thrombosis & Chemoprophylaxis, Anaemia, Anti-Adhesive & Anti-Inflammatory, Cataracts, Gaucher’s Disease, MPS-1 & IV, Cancer, Alzheimer’s Disease, Influenza Type A & B, and Others), Mode of Action [Inhibits Neuraminidase, Inhibits Heparanase and Selectins ... Read More
-
Global Enzyme Replacement Therapy Market - 2022-2029
... of 5.1 % during the forecast period (2022-2029). Enzyme Replacement Therapy (ERT) is the treatment involved for rare diseases. According to Global genes.org, around 80.0% of rare diseases are categorized under genetic origin. There are ... Read More
-
Glycomic Therapeutics Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Class (Isolated and Synthetic), Structures [Glycoproteins, Targeting Sialic Acid, Proteoglycans, Targeting Glycosaminoglycans, Glycosylphosphatidylinositol (GPI)-Anchored Proteins & Heparin Based Glycans, Targeting Glycosphingolipids, and Others], Indications (Thrombosis & Chemoprophylaxis, Anaemia, Anti-Adhesive & Anti-Inflammatory, Cataracts, Gaucher’s Disease, MPS-1 & IV, Cancer, Alzheimer’s Disease, Influenza Type A & B, and Others), and Mode of Action [Inhibits Neuraminidase; Inhibits Heparanase and Selectins and Blocks Interactions Between Growth Factors and Heparan Sulfate; Erythropoietin & Enzyme Replacement Therapy (ERT); Tissue Plasminogen Activator; Inhibits Glucosylceramide Synthase; Interleukin 1, 2 & 3; Beta & Gamma Interferons; and Others]
... Others], Indications (Thrombosis & Chemoprophylaxis, Anaemia, Anti-Adhesive & Anti-Inflammatory, Cataracts, Gaucher’s Disease, MPS-1 & IV, Cancer, Alzheimer’s Disease, Influenza Type A & B, and Others), and Mode of Action [Inhibits Neuraminidase; Inhibits Heparanase and Selectins ... Read More
-
Lysosomal Disease Treatment Market By Disease Type (Gaucher's Diseases, Fabry Diseases, Pompe’s Syndrome, Mucopolysaccharidosis, Others), By Type of Therapy (Enzyme Replacement Therapy, Stem Cell Therapy, Substrate Reduction Therapy, Others), By End User (Hospitals, Clinics, Others): Global Opportunity Analysis and Industry Forecast, 2021-2031
... Global Opportunity Analysis and Industry Forecast, 2021-2031 The global lysosomal disease treatment market was valued at $7,572.97 million in 2021, and is projected to reach $14,090.39 million by 2031, registering a CAGR of 6.4% from ... Read More
-
Lysosomal Storage Diseases Therapeutics Market, By Treatment (Enzyme Replacement Therapy (Stem Cell Therapy, Substrate Reduction Therapy, Others)), By Indication (Gaucher's Disease, Fabry Disease, Pompe’s Syndrome, Mucopolysaccharidosis, Others), By End U
... (North America Latin America Europe Asia Pacific Middle East Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028 The deficiency of enzymes that causes a specific disease condition called lysosomal storage disease includes ... Read More
-
Plant-based Biologics Market, by Product Type (Monoclonal Antibodies, Alpha Interferon, Glucocerebrosidase, Vaccines, and Others), by Source Type (Carrot, Tobacco Leaves, Rice Seeds, Alfalfa, and Others), by Disease Indication (Gaucher Disease, Tooth Deca
... Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028 Plant-based biologics are biologic drugs that are manufactured by using ... Read More
-
Gaucher's disease - Epidemiology Forecast to 2032
... France, and the United Kingdom), and Japan. Geographies Covered • The United States • EU5 (Germany, France, Italy, Spain, and the United Kingdom) • Japan Study Period: 2019-2032 Gaucher's disease Understanding The DelveInsight Gaucher's disease ... Read More
Research Assistance
